GW Pharma Bets On Europe For Epidiolex Growth
Sales Of Cannabinoid Steadily Rise In US
Executive Summary
The company expects the first ever plant-derived cannabinoid to be authorized in Europe to benefit from having already been used by over 1,100 patients with hard-to-treat forms of epilepsy in early access programs.
You may also be interested in...
UK’s NICE Not Convinced By Cannabis-Based Medicines
New draft guidance from the health technology assessment body NICE says that more evidence is needed on cannabis-based medicines before they can be more widely used. In the meantime, it says they should not be used in chronic pain, epilepsy or spasticity in multiple sclerosis, while nabilone may be used for chemotherapy-related sickness.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
C4XD Delisting Highlights Funding Frustration For UK Biotechs
The Manchester-based group has had enough of being undervalued in the public markets and is going private again.